PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of PepGen, Inc. (NASDAQ:PEPG) have earned an average rating of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $11.75.

PEPG has been the subject of several research reports. HC Wainwright upped their target price on shares of PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th.

PepGen Price Performance

Shares of PEPG opened at $5.36 on Wednesday. PepGen has a 1 year low of $0.88 and a 1 year high of $7.80. The stock’s fifty day moving average price is $5.73 and its two-hundred day moving average price is $4.02. The firm has a market cap of $368.50 million, a PE ratio of -1.90 and a beta of 1.91.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. Sell-side analysts anticipate that PepGen will post -2.73 earnings per share for the current fiscal year.

Institutional Trading of PepGen

Several hedge funds and other institutional investors have recently bought and sold shares of PEPG. Rangeley Capital LLC boosted its stake in shares of PepGen by 133.3% during the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after purchasing an additional 20,000 shares in the last quarter. Marshall Wace LLP purchased a new stake in PepGen in the second quarter worth about $44,000. Heights Capital Management Inc. bought a new stake in PepGen during the 3rd quarter valued at approximately $46,000. Burkehill Global Management LP bought a new stake in PepGen during the 3rd quarter valued at approximately $46,000. Finally, Militia Capital Partners LP purchased a new position in shares of PepGen during the 3rd quarter worth approximately $72,000. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).